BMG Pharma is an Italian B2B biotech company focused on the development and out-licensing of innovative patented products.
We offer a current and extensive portfolio of marketed products and a full development pipeline of new products based on our innovative Hyaluromimethic® Technology.
BMG is present in a diverse range of therapeutic areas including oral care, dermatology/aesthetics, osteoarthritis and women’s health.
Unique Hyaluromimethic® Technology
Hyaluromimethic® Technology is BMG’s patented state of the art technology of modifying Sodium Hyaluronate on its hydroxylic bonds. This novel technology with its outstanding features is suitable for the development of topical and injectable products in dermatology, ophthalmology, periodontology and more.